# Phase 244: guarded descriptive placebo scan integration

Date: 2026-11-08

## Scope
Read the published Phase 224 Bartlett HAC, Phase 242 placebo scan and Phase 243 calendar guard before adding an integration wrapper. Phase 242 previously allowed sorted ISO-looking weekend dates through its date checks; Phase 243 rejected weekend dates but was not called by Phase 242. The new additive wrapper calls the structural guard first and then invokes the existing descriptive scan. It accepts an optional exact caller-supplied session roster, but neither the roster nor its source is independently authenticated.

## Verification
Seven synthetic integration regression tests were authored. **These tests have not been executed in the original repository environment.** Attempted to download the three original dependencies for local execution, but the container could not resolve raw.githubusercontent.com. No pass count is asserted. The tests cover numerical contrasts, weekend rejection, Labor Day nonauthentication, roster mismatch, duplicates, incomplete windows and nonfinite values.

## Historical inference and identification
No SEC historical observations were retrieved or analyzed in this session. No new market estimates, causal claims, figures or statistical significance claims follow from this work. The substantial October 2025 placebo, September pretrends, treatment-roster authentication, selection and weighting sensitivity, exchange/security controls, matched-group and serial-dependence-aware inference remain unresolved. A weekday check does not authenticate a US exchange trading session, including holidays and exceptional closures.

## Archival inventory
Recovered historical ZIPs, source papers and chart packages were not available for verified import this session. Their complete inventory, licensing and redistribution permissions remain unverified. No archive was uploaded.

## Next executable work
Run the committed tests against the actual repository dependencies; obtain authoritative historical exchange-session records and authenticated SEC source inputs with checksums and provenance; then execute fixed-roster placebo and pretrend estimation with prespecified bandwidth and dependence-aware inference. The November 14 target is conditional, not a claim of publication readiness.
